Kornimate/medical-research-clean huggingface dataset:
trunk muscle strength and endurance in chronic ankle instability

Conditions: Chronic Ankle Instability

Summary: evaluation of trunk muscle strength in patients of chronic ankle instability

this study will be conducted in the isokinetic laboratory. sixty females with cai will participate in this study. their age will range from 18-30 years. they will be divided into two groups; the experimental and the control group. the experimental group will involve 30 females with cai and the control group will involve 30 healthy females. the isokinetic strength of trunk muscles will be evaluated in a concentric mode of muscle contraction at an angular velocity 60°/sec. mcgill test will be used to assess trunk muscle endurance.

Eligibility criteria:
inclusion criteria: * the initial sprain must have occurred at least 12 months prior to study enrollment. * the most recent injury must have occurred more than three months prior to study enrollment (unassisted walking without limping for at least three months after injury). * a history of the previously injured ankle joint giving way, recurrent sprain and/or feelings of instability. * the injured/unstable ankle functionally weaker, more painful, looser, and less functional than the uninvolved ankle. * the oswesty disability index (odi) score for both groups is from 0 to 20% (minimal disability) (fairbank and pynsent, 2000). 6- the identification of functional ankle instability questionnaire (idfai) score is less than 10 for the experimental group and 11 or more for the control group (simon et al., 2012). exclusion criteria: * 1-a history of previous surgeries or fractures in either limb of lower extremity. 2-acute injury to musculoskeletal structures of other joints of the lower extremity in the previous three months, which impacted joint integrity and function (ie, sprains, fractures) resulting in at least one interrupted day of desired physical activity. 3-any positive ﬁndings of the anterior drawer or talar tilt test (hubbard and kaminski, 2002). 4-any shoulder (kibler et al., 2006) or elbow injuries (ben kibler and sciascia, 2004).

Keywords: cai
effect of remote ischemic postcondioning on glymphatic system in acute stroke

Conditions: Stroke

Summary: investigators aimed to investigate the changes of glymphatic function after remote ischemic postcondioning treatment in acute ischemic stroke .


Eligibility criteria:
inclusion criteria: * the patient was 18-80 years old; * the nihss score was ≤ 25 and nihss \> 5，glasgow coma score ≥ 8; * the patients were diagnosed as anterior circulation cerebral infarction and could start remote ischemic postcondioning within 24 hours after onset * normal to random time within 24 hours * written informed consent signed by patients or their families exclusion criteria: * patients receiving thrombolysis or endovascular therapy; * modified rankin scale (mrs) score ≥ 2 before this attack; * other intracranial lesions, such as cerebral hemorrhage, cerebral venous disease, severe subclavian artery stenosis and other diseases involving the brain; * arterial blood pressure ≤ 90/60mmhg or ≥ 180/100mmhg after treatment.
therapy with topotecan and carboplatin by patients with relapsed ovarian cancer

Conditions: Ovarian Cancer

Summary: compatibility of the topotecan therapy in combination with carboplatin.

the aim of the study was to confirm the tolerability of 3-day topotecan therapy in combination with carboplatin in accordance with published data and to investigate the tolerability of continued therapy until disease progression or up to a maximum of 12 months.

Eligibility criteria:
inclusion criteria: * age \>= 18 years * patient with ovarian cancer after primary therapy * bone marrow function leukocytes \>= 4,0 x 109/ l, platelets \>= 100 109/l, hemoglobin \>= 9 g/dl * renal function creatinin \ = 60 ml/min * liver function bilirubin \<= 2,0 mg/dl, sgot, sgpt and ap within 3 fold of the reference laboratory's normal range * ecog \<= 2 * intention of regular follow-up visits for the duration of the study * written informed consent exclusion criteria: * any known hypersensitivity against topotecan isomerase-i-inhibitor other medication included in the study protocol * ecog \> 2 * patients with radiotherapy within the last 4 weeks

Keywords: platin-resistant
financial and insurance assistance- oncology financial and legal navigation program

Conditions: Financial Stress; Pediatric Cancer

Summary: the overall objective of this study was to develop and evaluate finassist (financial and insurance navigation assistance), a patient-centered, interdisciplinary team-based oncology financial and legal navigation program. the program leverages medical legal partnerships to enhance cost of care conversations with pediatric oncology patients and caregivers. finassist optimizes the team-based care model by integrating clinicians, social workers, financial navigators, and legal advocates who work in tandem to enhance cost of care conversations with patients and caregivers, identify and intervene on patient socio-legal needs, and advocate for system-level changes.


Eligibility criteria:
inclusion criteria: * caregivers of patients who have any cancer or hematologic disorder diagnosis at the danceblue pediatric hematology/oncology clinic at kentucky children's hospital * patients with childhood cancers and/or hematologic disorders at the danceblue pediatric hematology/oncology clinic at kentucky children's hospital * 18 years and older exclusion criteria: * unable to provide consent

Keywords: financial toxicity hardship cost conversations finassist
anatomic anterior cruciate ligament with short hamstring graft compare with a standard hamstring graft technique

Conditions: Anterior Cruciate Ligament Injuries

Summary: this study was to evaluate the functional outcome of quadruple hamstring graft in femoral tunnel less than 15 mm and morethan or equal 15 mm of acl reconstruction. the hypothesize that no difference intermediate follow up ( 6 month - 24 month) of functional outcome and clinical evaluation between short and normal femoral tunnel graft length of hamstring tendon acl reconstruction.

the patient recruitment (n=29) and baseline data collection were done at our institute between march2014-september 2015. the inclusion criteria were patients with anterior cruciate ligamentous injury who needed ligamentous reconstruction, closed growth plates and younger than 60 years old, absence of ligament injury to the opposite knee. the exclusion criteria are patients who did not want to participate in this study or patient with failed anterior cruciate ligamentous reconstruction. all the procedure of anterior cruciate ligament reconstructions were performed by the senior authors (b.c). semitendinosus and gracilis tendons were harvested through an oblique approach medial to the tibial tubercle in all patients. complete anterior cruciate ligament was confirmed at arthroscopy. associated intra-articular injuries such as meniscus tear and cartilage lesions were fixed at of the index operation .the femoral tunnel were drilled though the am portal.

Eligibility criteria:
inclusion criteria: * patients with anterior cruciate ligamentous injury with the diagnosis of injured ligaments was made based on a detailed history of the knee injury, physical examination on pathologic status and abnormal laxity, routinely performed plain radiographs and mri scans, and the findings at surgery. * patients who have closed growth plates. * patients who younger than 60 years old. * patients who absence of ligament injury to the opposite knee. exclusion criteria: * patients with a combined ligament injury as folling: 1. posterior cruciate ligament 2. the lateral collateral ligament 3. the posterolateral corner structures of the knee 4. medial collateral ligament.

Keywords: acl short hamstring graft standard hamstring graft
green digital diabetes waste project

Conditions: Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetes Mellitus, Type 1

Summary: the purpose of this study is to determine how people with diabetes are disposing of various products and devices and at what rates so that better devices with less waste can be designed in the future.

the study aims to compare the amount of environmental waste that is generated during the management of diabetes of participants who are using a cgm and on multiple daily injection (mdi) or using an aid (automated insulin delivery) system. this study is expected to demonstrate which devices create the most waste and where opportunities exist to decrease diabetes device waste. we will collect data to describe both quantitatively (via daily survey) and qualitatively (via photography) the types of waste that are generated during the management of diabetes.

Eligibility criteria:
inclusion criteria: * person with diabetes (self-identified), either type 1 or type 2, who has been diagnosed at least 6 months earlier * age 18 years and above * use of a cgm * use of an insulin pump or on mdi * access to the internet and e-mail * access to a smartphone with photographic capability * able and willing to provide informed consent exclusion criteria: * failure to meet any of the inclusion criteria * any condition which, in the opinion of an investigator, would make the subject not qualified to participate in the study. * adults unable to consent * adults unable to speak english * individuals who are not yet adults (infants, children, teenagers) * pregnant women * prisoners * cognitively impaired adults

Keywords: continuous glucose monitor type 1 diabetes mellitus type 2 diabetes mellitus multiple daily injection insulin pump diabetes waste
assessment of the association between metabolic associated fatty liver disease (mfld) and biopsy proved cases of gn

Conditions: Assessment of Patients With Biopsy Proven Primary Glomerulonephritis Above 18 Years of Age for MFLD Development

Summary: fatty liver disease is a global health concern with a prevalence of about 25% amongst united states. its increased prevalence is attributed to increase in patients with obesity and metabolic syndrome (1). diabetes mellitus (dm),obesity, hyperinsulinemia are predisposing factors for fatty liver disease(2). glomerulonephritis (gn), a complex syndrome encompassing a variety of individual disorders, is associated with significant morbidity and mortality(3). given its association with hyperlipidaemia, metabolic syndrome and long-term use of steroid there is concern that patients with gn may be at increased risk of fatty liver disease patients with ns are frequently found to have fatty liver disease even when adjusting for common risk factors(1). it is known that obesity is an independent risk factor for ckd and it is associated with the development of proteinuria and pathologic findings of podocyte hypertrophy and focal segmental glomerular sclerosis even in the absence of diabetes and hypertension . in addition, studies have shown that obesity as well as metabolic syndrome is a strong predictor of the development of fatty liver disease (4) . hence, clinicians should maintain a high index of suspicion regarding presence of nafld in patients with ns


Eligibility criteria:
inclusion criteria: * patients with biopsy proven primary glomerulonephritis. * age \>18 years exclusion criteria: 1. patients with e-gfr\<60ml/min/1.73m2 2. patients with secondary glomerulonephritis 3. patients with body mass index \>35 kg/m2 4. patients known to be diabetic. 5. patients known to be hypertensive. 6. patients with hcv or hbv infection either acute or chronic 7. patients with acute hepatitis whatever the aetiology 8. patients with autoimmune diseases
surefire catheter versus standard end-hole microcatheter: a pilot study

Conditions: Hepatocellular Carcinoma

Summary: the surefire infusion system is a novel catheter initially developed to prevent reflux of embolic material into non-target vascular territories. further research has demonstrated improved penetration and distribution of embolic material into treated arterial territories. the purpose of this study is to compare y-90 glass microsphere distribution and penetration into cancerous tissue within the liver between a standard endhole catheter and the surefire infusion system.

yttrium-90 (y-90) radioembolization is a minimally invasive trans-arterial treatment for primary and secondary hepatic malignancies that relies on tumor hypervascularity for concentration of radioactive microspheres. the surefire® infusion system (sis) (westminster, co) was developed to reduce non-target embolization which can result in morbid complications, especially those involving radioembolic or drug eluting microspheres. prior to its introduction, radioembolization and other trans-arterial therapies have been performed with standard end-hole catheters. in addition to providing protection against non-target embolization, studies have demonstrated improved penetration of embolic material (tantalum microspheres and tc-99m labeled maa) with the use of the sis when compared to conventional end-hole catheters. to date, no study has demonstrated improved distribution and penetration of yttrium-90 glass microspheres with the use of the surefire catheter versus a standard end-hole catheter. y-90 distribution can be evaluated with the use of immediate post-delivery pet/ct imaging as it creates its own pair production and can be imaged in the immediate post delivery period. pet/ct will demonstrate distribution and the dose to tumors can be calculated. the investigators propose a pilot study comparing yttrium-90 tumor distribution and concentration in patients with hepatocellular carcinoma (hcc) with the use of the sis versus a standard end-hole catheter.

Eligibility criteria:
inclusion criteria: * lobar-only treatments * patients with biopsy or radiographically proven hepatocellular carcinoma who are not candidates for transplant, surgical resection or ablative therapy * patients 18 years of age and older * patients who are able to provide written informed consent exclusion criteria: * patients with barcelona-clinic liver cancer (bclc) stage c disease, * patients with eastern cooperative oncology group (ecog) performance status ≥ 3, * patients who are unable to tolerate y-90, * patients with arterial anatomy unsuitable to place surefire catheter, * patients with uncorrectable coagulopathy, * patients with platelets less than 50 (uncorrectable), * bilirubin \>3 mg/dl, * ast or alt\>5x upper limit of normal, * patients who are unable to tolerate angiography, * patients with \< 3 months to live, * patients who meet the standard y-90 exclusion criteria according to package insert * female patients who are pregnant * patients under the age of 18 * patients who are unable to provide written informed consent
virtual reality to reduce anxiety in ambulatory surgical operations

Conditions: Anxiety

Summary: background. preoperative anxiety is a common problem for patients who undergo surgical operations, being often associated with a number of negative behaviours during and after the surgical experience. since drug treatments alone have frequently proved to be inadequate to reduce stress and anxiety in surgical contexts, in the last decades there has been an increased interest in non invasive complementary and alternative medical therapies (cam), including music, relaxation, guided imagery, hypnosis, etc. that reduce pain and tension during pre and post operative phases. virtual reality can be considered an innovative form of e-health-based cam therapy having gained recognition as a means of attenuating pain during medical procedures. vr reduces distress and pain perception by providing a particularly intense form of immersive distraction that taxes the patient's limited attention capacity, resulting in the withdrawal of attention from the real, noxious, external stimulus with a subsequent reduction in pain and stress. objective. the aim of this study is to test the efficacy of a small, portable and immersive virtual reality system to reduce anxiety in a sample of patients who underwent ambulatory surgical operations under local or regional anaesthesia.


Eligibility criteria:
inclusion criteria: * all patients who undergo ambulatory surgical operations and sign informed consent exclusion criteria: * death or blind patients

Keywords: immersive virtual reality e-health surgery anxiety relaxation patients who undergo ambulatory surgical operations
the effects of giving interleukin-2 (il-2) plus anti-hiv therapy to hiv-positive patients with cd4 cell counts of at least 350 cells/mm3

Conditions: HIV Infections

Summary: the purpose of this study is to evaluate the safety and tolerability of giving il-2 plus anti-hiv (antiretroviral) therapy to hiv-positive patients with cd4 cell counts (cells of the immune system that fight infection) of at least 350 cells/mm3. this study will also examine the ability of antiretroviral therapy combined with il-2 to boost the immune system. il-2, given through injection under the skin, in combination with anti-hiv therapy can increase cd4 cell counts. this study examines 3 doses of il-2 in order to determine the safest and most effective dose to use.

il-2, administered subcutaneously in combination with antiretrovirals, has resulted in increased cd4+ cell counts which may retard hiv disease progression. using a smaller patient sampling, this phase ii study helps develop the clinical experience needed to consider formation of a larger, more complete phase iii trial. seventy-two hiv-infected patients (previously treated or naive) are randomized independently to receive either control therapy with antiretrovirals alone or escalating doses of subcutaneous interleukin-2 (il-2) plus antiretrovirals. in the absence of dose-limiting toxicity (dlt) in at least 9 of 12 patients in group 1, 12 additional patients are entered into group 2 and treated as indicated. in the absence of dlt in 9 of 12 patients in group 2, the final 12 patients are entered into group 3. those patients enrolled in either of the first 2 dose groups who complete 3 courses of therapy have their dose escalated to a maximum dose. a course of treatment is defined as 5 days of il-2 plus antiretrovirals followed by 7 weeks of antiretroviral therapy alone.

Eligibility criteria:
inclusion criteria patients may be eligible for this study if they: * are hiv-positive. * have a cd4 cell count greater than or equal to 300 cells/mm3. * have no aids-defining illnesses. * are at least 18 years old. * have been on antiretroviral therapy for at least 7 days prior to study entry. exclusion criteria patients will not be eligible for this study if they: * abuse alcohol or drugs, or have any serious psychiatric or medical illnesses that would affect their safety or ability to complete the study. * have a history of the following: cancer (other than kaposi's sarcoma), an aids-defining illness, a central nervous system abnormality, or an autoimmune/inflammatory disease. * are pregnant or breast-feeding. * have ever received il-2.

Keywords: hiv-1 interleukin-2 dose-response relationship, drug antiviral agents cd4 lymphocyte count dna, viral
semaglutide in auto-hsct

Conditions: Intestinal Mucositis; Inflammation; Chemotherapeutic Toxicity

Summary: the primary objective of this clinical trial is to ievaluate the effect of semaglutide (glp-1 receptor agonist) in reducing intensity of gastrointestinal (gi) mucositis in patients undergoing high-dosage chemotherapy followed by autologous (auto) haematopoietic stem cell transplantation (hsct). the secondary objective is to evaluate the effect and safety of semaglutide in reducing gut barrier injury and systemic inflammation in patients undergoing auto-hsct. study design: the study is designed as a randomized, double-blind, placebo-controlled, phase 2, two-centre investigator-initiated clinical study. patients referred for treatment with high-dose chemotherapy and auto-hsct will be randomized in a 1:1 manner to receive either semaglutide or placebo. the study includes a run-in period 3 to 4-week low-dose period with semaglutide subcutaneously (s.c.) 0.25 mg once-weekly (qw) prior to high-dose chemotherapy treatment followed by a period of 4 to 5 weeks with semaglutide 0.5 mg qw. total duration of treatment with investigational drug will be 8 weeks. total study duration for the individual patients will be 20-22 weeks, including a 2-4-week screening period and 10 weeks of follow-up. study population: a planned total number of 40 patients will be randomized.


Eligibility criteria:
inclusion criteria: * referral for auto-hsct for relapsed diffuse large b-cell lymphoma or follicular lymphoma * age ≥ 18 years * bmi ≥ 18.5 * ecog performance status\* ≤ 2 * literate in danish and/or english exclusion criteria: * diabetes * inflammatory bowel disease * previous or current gastrointestinal malignancy * personal or family history of medullary thyroid carcinoma or men syndrome * genetic disorders with defective tissue repair (e.g., fanconi anaemia) * history of pancreatitis (acute or chronic) * renal impairment measured as egfr value of \< 30 ml/min/1.73 m2 * impaired liver function, defined as alanine aminotransferase ≥ 2.5 times upper normal limit at screening * known or suspected hypersensitivity to semaglutide or other glp-1ra * pregnant or nursing females

Keywords: gut epithelial barrier chemotherapy-induced toxicity growth factor
ct guided injection for low back radiculopathy: a randomized clinical trial

Conditions: Disc Herniation; Lumbosacral Radiculopathy

Summary: herniated disc sometimes cause back pain radiating down to a leg. this pain can be so severe that it is functionally disabling. the purpose of this randomized clinical trial is to determine if corticosteroid medication, delivered directly to the area near the herniated disc, can improve the pain and functional disability associated with a herniated disc.


Eligibility criteria:
inclusion criteria: * adults \<60y * \< 1m of symptoms * symptoms consistent with herniated disc * mri demonstrates corresponding disc * back pain resulting in functional disability exclusion criteria: * chronic pain * daily pain medication * frequent back pain * on the job injury

Keywords: disc herniation lumbosacral radiculopathy corticosteroids